Author

R. J. Lew

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 1 Bioengineering· 1 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Organism:bacteria (other)· 1 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Assay:DNA methylation· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

J. A. Doudna· 3 shared C. Fellmann· 2 shared A. E. Dejanov· 1 shared A. M. Amen· 1 shared A. M. McKinney· 1 shared A. Mancini· 1 shared A. Marson· 1 shared B. McMahon· 1 shared

Activity by Year

2019-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 22 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersBioengineering

J. A. Doudna

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

CRISPR-Cas9 mediated nuclear transport and genomic integration of nanostructured genes in human primary cells

E. Lin Shiao, W. G. Pfeifer, B. R. Shy, M. S. Doost, E. Chen, V. S. Vykunta, J. R. Hamilton, E. C. Stahl, D. M. Lopez, C. R. S. Espinoza, A. E. Dejanov, R. J. Lew, M. G. Poirer, A. Marson, C. E. Castro, J. A. Doudna

This study delivers DNA nanostructures into human primary cells using CRISPR-Cas9, achieving efficient genomic integration with lower toxicity than dsDNA.

bioRxiv · Nov 8, 2021 · PreprintBioengineering

Cancer-specific loss of TERT activation sensitizes glioblastoma to DNA damage

A. M. Amen, C. Fellmann, K. M. Soczek, S. M. Ren, R. J. Lew, G. J. Knott, J. E. Park, A. M. McKinney, A. Mancini, J. A. Doudna, J. F. Costello

This study shows that reducing GABPB1L in TERT-mutant glioblastomas, combined with chemotherapy, reduces tumor growth by impairing DNA damage response.

Proceedings of the National Academy of Sciences · Mar 23, 2021Peer-reviewedCancer Biology

Potent CRISPR-Cas9 inhibitors from Staphylococcus genomes

K. E. Watters, H. Shivram, C. Fellmann, R. J. Lew, B. McMahon, J. A. Doudna

This study identifies three new potent CRISPR-Cas9 inhibitors from Staphylococcus genomes, showing they specifically block SauCas9 activity in human cells.

bioRxiv · Oct 9, 2019Biochemistry